GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) » Definitions » Cyclically Adjusted Revenue per Share

GlaxoSmithKline Pharmaceuticals (BOM:500660) Cyclically Adjusted Revenue per Share : ₹223.59 (As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2025 was ₹57.528. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹223.59 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-31), GlaxoSmithKline Pharmaceuticals's current stock price is ₹3295.00. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹223.59. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 14.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pharmaceuticals was 13.51. The lowest was 8.80. And the median was 12.19.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 223.59

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 220.30 223.84 224.45 223.59

Competitive Comparison of GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=57.528/157.5517*157.5517
=57.528

Current CPI (Mar. 2025) = 157.5517.

GlaxoSmithKline Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200712 0.000 51.259 0.000
200812 0.000 56.232 0.000
200912 0.000 64.648 0.000
201012 0.000 70.768 0.000
201112 0.000 75.359 0.000
201212 0.000 83.774 0.000
201312 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201706 34.418 107.109 50.627
201803 0.000 109.786 0.000
201806 43.397 111.317 61.422
201809 48.171 115.142 65.914
201812 48.721 115.142 66.666
201903 42.549 118.202 56.714
201906 46.498 120.880 60.604
201909 52.070 123.175 66.602
201912 45.962 126.235 57.364
202003 44.235 124.705 55.886
202006 38.273 127.000 47.480
202009 51.860 130.118 62.794
202012 46.750 130.889 56.273
202103 42.370 131.771 50.660
202106 42.421 134.084 49.846
202109 55.158 135.847 63.971
202112 48.190 138.161 54.954
202203 46.962 138.822 53.298
202206 43.976 142.347 48.673
202209 54.134 144.661 58.958
202212 47.340 145.763 51.169
202303 44.999 146.865 48.274
202306 44.980 150.280 47.156
202309 56.493 151.492 58.753
202312 47.555 152.924 48.994
202403 54.881 153.035 56.501
202406 48.076 155.789 48.620
202409 59.686 157.882 59.561
202412 56.045 158.323 55.772
202503 57.528 157.552 57.528

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GlaxoSmithKline Pharmaceuticals  (BOM:500660) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3295.00/223.59
=14.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pharmaceuticals was 13.51. The lowest was 8.80. And the median was 12.19.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines